Exclzyme® EN - Clinical Trials
|I Product Info||I Ingredients||I Recommended Use||I Clinical Trials||I Research Brief||I References|
Indication: enzymatic deficiency, indigestion, dysbolism, degenerative changes in joints, increased blood viscosity, inflammations, traumas, wounds, postoperative recovery period.
Actions: improves digestion, regulates metabolism, has an anti-inflammatory and analgetic effect, has immunomodulatory, antiaggregatory, and fibrinolytic action, stimulates enzyme activity, speeds up the wound healing.
Ingredients (per 1 tablet):
Exclzyme®EN – 250 mg (30,000 EU): Peptizyme SP®EN, protease, papain, bromeline, amylase, lipase, rutin, amla (Emblica Officinalis).
Low USA domestic & international shipping
Exclzyme® EN - Clinical Trials:
Numerous researches have shown the positive effect of systemic enzymes on faster healing of traumas in sportsmen, as well as tissue restoration after surgeries.
In one study of football players suffering from ankle injuries, proteolytic enzyme supplements accelerated healing and got players back on the field about 50% faster than athletes assigned to receive a placebo tablet. (17)
Another study on athletes, have shown that enzymes can help reduce inflammation, speed up healing of bruises and other tissue injuries (including fractures) and reduce overall recovery time, when compared to athletes taking a placebo. (18)
In patients recovering from facial and various reconstructive surgeries, treatment with proteolytic enzymes significantly reduced swelling, bruising and stiffness compared to placebo groups. (19)
One double-blind study was conducted by German researchers to determine the effect of Serrapeptase on post-operative swelling and pain. This study involved sixty-six patients who were treated surgically for fresh rupture of the lateral collateral ligament of the knee. On the third post-operative day, the group receiving Serrapeptase exhibited a 50 percent reduction of swelling, compared to the controls. The patients receiving Serrapeptase also became pain-free more rapidly than the controls, and by the tenth day, the pain had disappeared completely.
Serrapeptase has been used in the successful treatment of fibrocystic breast disease. In a double-blind study, Serrapeptase was superior to the placebo for improvement of breast pain, breast swelling and induration (firmness). 85.7 percent of the patients receiving Serrapeptase reported moderate to marked improvement. No adverse reactions to Serrapeptase were reported. Researchers concluded that Serrapeptase is a safe and effective method for the treatment of breast engorgement.
Due to its anti-inflammatory properties, Serrapeptase has been shown in clinical studies to benefit chronic sinusitis sufferers. In this condition, the mucus in patients’ nasal cavities is thickened and hypersecreted. This thickening causes mucus to be expelled less frequently. Japanese researchers evaluated the effects of Serrapeptase (30 mg/day orally for four weeks) on the elasticity and viscosity of the nasal mucus in adult patients with chronic sinusitis. Serrapeptase reduced the viscosity of the mucus, improving the elimination of bronchopulmonary secretions.
Other clinical trials support Serrapeptase’s ability to relieve the problems associated with ear, nose, and throat infection, anosmia (loss of smell), nasal obstruction, laryngitis, difficulty in swallowing, often in just 3-4 days. Physicians assessed efficacy of treatment as excellent or good for 97.3 percent of patients treated with Serrapeptase compared with only 21.9 percent of those treated with a placebo.
Hans A. Nieper, M.D., an internist from Hannover, Germany, studied the effects of Serrapeptase on plaque accumulations in the arteries. The formation of plaque involves deposits of fatty substances, cholesterol, cellular waste products, calcium and fibrin (a clotting material in the blood) on the inner lining of the arteries. Excessive plaque results in partial or complete blockage of the blood’s flow through an artery, resulting in arteriosclerosis, and potentially a stroke or heart attack.
According to Dr. Nieper, 30,000 I.U. of Serrapetase per day for 12 to 18 months is sufficient to remove fibrous blockages from constricted coronary arteries, as confirmed in many of his patients by ultrasound examination.
Proteolytic enzymes have a long history of use in cancer treatment. Back in 1906, a Scottish embryologist John Byrd in his book “The Enzyme Treatment of Cancer and its Scientific Basis” reported the successful treatment of cancer using pancreas extract. In his proposed theory he claims that cancer development takes place, because pancreas do not produces sufficient amount of enzymes to fight cancer cells.
Proteolytic enzymes have been promoted by numerous alternative cancer practitioners for many years, but most recently by Nicholas Gonzalez, M.D., who is evaluating the benefits of proteolytic enzymes in patients with advanced pancreatic cancer in a large-scale study, funded by the National Institute of Health, National Center for Complementary and Alternative Medicine, with collaboration from the National Cancer Institute. This major study showed striking results. (20)
In one of researches it was established, that oral proteolytic enzymes intake is not less effective treatment of herpes, than standard medicamentous treatment (acyclovir (Zovirax)). (21)
Proteolytic enzymes are successfully applied for treatment of hepatitis C patients, and that is confirmed by laboratory researches. (22)
The study conducted to determined the positive effect of Exclzyme®EN for reduction of inflammation and painful sensations.
In the single blind controlled parallel research 100 patients with inflammatory processes of a traumatic, infectious, post operational and dental origin took part. In research various dozes of Exclzyme®EN were applied.
Effect of Exclzyme®EN on reduction of painful sensations, inflammatory process, side-effects, improvement of blood work results and mobility in relation to control group was observed.
The results of the research:
Subjective painful sensations while using Exclzyme®EN (2.1 g/per day) and Ibuprofen (1.2 g/per day) were identical in the beginning of the experiment, and have completely stopped in both groups on the fifth day. (pic. 1)
As you can see from the table (pic.2), on the seventh day of the research the patients, who took Exclzyme®EN (daily dose of 2.1 g.) showed, that all signs of inflammation (redness, edema, pain at movement) had disappeared. While in the group of patients who took Ibuprofen (1.2 g. a day) there was edema (in one case), and with Exclzyme®EN (1.05 g. per day) – redness (in one case).
Exclzyme®EN is effective in reduction of painful sensations and inflammation. Side effects were not observed.